Stockscreener 앱 받기
3.81
3.30%
-0.13
시간 외 거래:
3.82
0.010
+0.26%
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Protara Therapeutics Stockholders Approve Governance and Share Increases - TipRanks
Protara Therapeutics (TARA) investors approve share increase and pay items - Stock Titan
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Protara Therapeutics (TARA) Dips 3.8% as Stock Nears Key Support LevelTrend Following Picks - newsline.com
Protara Therapeutics Q1 2026 Earnings: EPS Beat Driven by Expense Management, Stock SlipsStrong Earnings Momentum - newsline.com
Protara Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SentimentProduct Revenue Analysis - newsline.com
Protara Therapeutics (NASDAQ: TARA) CCO has 6,008 RSU shares withheld for taxes - Stock Titan
Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
What's Driving Protara's Recent Surge - Kavout
Protara Therapeutics (TARA) Dips 2% as Stock Hovers Near SupportCharm Flow - The Legal Advocate
Protara Therapeuticsenters sales agreement with TD Cowen for common stock offering - marketscreener.com
Protara Therapeutics (NASDAQ: TARA) secures $100M ATM sales agreement with TD Cowen - Stock Titan
Protara Therapeutics (TARA) Q1 2026 Earnings: Narrower Loss Beats Street Estimates on Cost Management - The Legal Advocate
TARA: TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, with key H2 catalysts - TradingView
TARA: TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, targeting broad markets - TradingView
Protara’s cell therapy shows treatment durability in mid-stage NMIBC study - MSN
[EFFECT] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara Therapeutics Q1 2026 Earnings: EPS Beat Despite No Revenue; Stock DeclinesTangible Book Value - newsline.com
Protara Therapeutics Q1 2026 Earnings: EPS Beats Estimates Amid Continued Pipeline ProgressEstimate Accuracy - newsline.com
Piper Sandler initiates coverage of Protara Therapeutics (TARA) with overweight recommendation - MSN
Protara Therapeutics Inc stock (US87612E1064): analyst optimism contrasts with volatile share price - AD HOC NEWS
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $24 to $28 - Moomoo
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV) - The Globe and Mail
Piper Sandler Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $24 - Moomoo
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Protara Therapeutics (TARA) - The Globe and Mail
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic MalformationsSlideshow (NASDAQ:TARA) 2026-05-20 - Seeking Alpha
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $25 to $27 - Moomoo
TARA Maintained by Oppenheimer -- Price Target Raised to $28.00 - GuruFocus
Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating - Moomoo
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Cantor Fitzgerald reiterates Protara Therapeutics stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Protara Therapeutics stock rating - Investing.com
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - The Manila Times
H.C. Wainwright reiterates Protara stock rating citing LM data By Investing.com - Investing.com Canada
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Raises Target Price to $25 - Moomoo
TARA: TARA-002 delivers strong, durable efficacy and safety for lymphatic malformations, targeting FDA approval - TradingView
J.P. Morgan Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Protara Therapeutics reports 55% complete response rate in bladder cancer study - MSN
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 - Sahm
Protara Therapeutics (TARA) Stock Analysis: Falls -0.65%, Watching $4.34 2026-05-19Long Short Pair - newsline.com
protara therapeutics, inc. Earnings dates - RTTNews
Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program - Quiver Quantitative
Protara Therapeutics to Host Virtual Investor Webinar to - GlobeNewswire
Protara Therapeutics Inc stock (US87612E1064): bladder cancer data put small-cap biotech in focus - AD HOC NEWS
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Protara Therapeutics (TARA) Unveils Promising Phase 2 Trial Resu - GuruFocus
Janus Henderson (TARA) disclosed 5.21M-share, 9.6% stake in Protara - Stock Titan
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study - Benzinga
Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA) - The Globe and Mail
Protara reports 12-month data for bladder cancer therapy By Investing.com - Investing.com South Africa
Protara reports 12-month data for bladder cancer therapy - Investing.com
1.27%
1.43%
자본화:
|
볼륨(24시간):